A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 (NCT04879329)
A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination With Pembrolizumab in Subjects With Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2
🩺 Plain-English Summary (8th-Grade Level)
This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants. Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic). It will also study what side effects happen when participants get the drug. A side effect is anything a drug does to your body besides treating the disease.
Who can join: Review the eligibility criteria below.
Location: Banner Gateway Medical Center — Gilbert, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (221 Sites)
Showing the first 25 of 221 sites.
- Banner Gateway Medical Center — Gilbert, Arizona
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- Kaiser Permanente Anaheim Kraemer Medical Offices — Anaheim, California
- Foothill Cardioology — Arcadia, California
- Kaiser Permanente Baldwin Park Medical Center — Baldwin Park, California
- Kaiser Permanente Bellflower Medical Offices — Bellflower, California
- Beverly Hills Multi-Specialties Practice — Beverly Hills, California
- Providence Saint Joseph Medical Center — Burbank, California
- UCLA Burbank Cardiology — Burbank, California
- UCLA Hematology/Oncology - Burbank — Burbank, California
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center) — Duarte, California
- UCLA Encino Specialty Care (Radiology) — Encino, California
- UCLA Hematology/Oncoclogy-Encino — Encino, California
- Kaiser Permanente Fontana Medical Center — Fontana, California
- Foothill Cardiology Glendora — Glendora, California
- Kaiser Permanente South Bay Medical center — Harbor City, California
- Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- Kaiser Permanente Alton/Sand Canyon Medical Offices — Irvine, California
- UCLA Downtown Los Angeles Primary & Specialty Care — Los Angeles, California
- Kaiser Permanente Los Angeles Medical Offices — Los Angeles, California
- Kaiser Permanente West Los Angeles Medical Center — Los Angeles, California
- Valkyrie Clinical Trials — Los Angeles, California
- Ronald Reagan UCLA Medical Center, Drug Information Center — Los Angeles, California
- UCLA Cardiovascular Center — Los Angeles, California
- UCLA Hematology Oncology — Los Angeles, California
📞 Contact the Study Coordinator
Phone: (800) 718-1021
Email: ClinicalTrials.gov_Inquiries@pfizer.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Urothelial Carcinoma
- Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) — Springdale, Arkansas
- Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma — Philadelphia, Pennsylvania
- A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma — Houston, Texas
- A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder — Bloomington, Indiana
- Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma — Oklahoma City, Oklahoma
- Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC — Tampa, Florida
Explore by condition: All Urothelial Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.